• 3070 Bristol Pike, Suite 112, Bensalem, PA 19020

  • Call Us: (215) 638-4847 |

    Fax: (215) 638-4867

ImmunityBio, Inc. (NASDAQ: IBRX)

Case Details

Join The Class Action
This lawsuit is for anyone who acquired securities in ImmunityBio, Inc. (NASDAQ: IBRX) from May 23, 2022 through May 10, 2023.
 
The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that it could manufacture its drug, Anktiva, safely such the the drug could receive FDA approval, but then by failing to take sufficient care to assure the safe manufacture of Anktiva.
 

On May 11, 2023, before the market had opened, ImmunityBio announced that the FDA had rejected the Biologics License Application for the Company’s immunotherapy drug, Anktiva, due to “deficiencies relat[ing] to the FDA’s pre-license inspection of the Company’s third-party contract manufacturing organizations.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

 
The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in ImmunityBio, Inc. (NASDAQ: IBRX) from May 23, 2022 through May 10, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.